191 related articles for article (PubMed ID: 27066860)
1. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
Nasser AF; Henderson DC; Fava M; Fudala PJ; Twumasi-Ankrah P; Kouassi A; Heidbreder C
J Clin Psychopharmacol; 2016 Apr; 36(2):130-40. PubMed ID: 26862829
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study.
Dhanda R; Varghese D; Nadipelli VR; Fava M; Joshi N; Solem CT; Graham JA; Learned SM; Heidbreder C
Patient Prefer Adherence; 2019; 13():1037-1050. PubMed ID: 31308636
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
Nasrallah HA; Duchesne I; Mehnert A; Janagap C; Eerdekens M
J Clin Psychiatry; 2004 Apr; 65(4):531-6. PubMed ID: 15119916
[TBL] [Abstract][Full Text] [Related]
5. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
Ivaturi V; Gopalakrishnan M; Gobburu JVS; Zhang W; Liu Y; Heidbreder C; Laffont CM
Br J Clin Pharmacol; 2017 Jul; 83(7):1476-1498. PubMed ID: 28133766
[TBL] [Abstract][Full Text] [Related]
6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
8. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.
Hertling I; Philipp M; Dvorak A; Glaser T; Mast O; Beneke M; Ramskogler K; Saletu-Zyhlarz G; Walter H; Lesch OM
Neuropsychobiology; 2003; 47(1):37-46. PubMed ID: 12606844
[TBL] [Abstract][Full Text] [Related]
9. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
10. Long-acting risperidone: a review of its use in schizophrenia.
Harrison TS; Goa KL
CNS Drugs; 2004; 18(2):113-32. PubMed ID: 14728058
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
12. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
[TBL] [Abstract][Full Text] [Related]
13. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
[TBL] [Abstract][Full Text] [Related]
14. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
15. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
Gharabawi GM; Greenspan A; Rupnow MF; Kosik-Gonzalez C; Bossie CA; Zhu Y; Kalali AH; Awad AG
BMC Psychiatry; 2006 Oct; 6():45. PubMed ID: 17054789
[TBL] [Abstract][Full Text] [Related]
16. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
[TBL] [Abstract][Full Text] [Related]
17. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.
Chen ZH; Wang GH; Wang XP; Huo YX; Yang MH; Li L; Mei HB
Clin Rehabil; 2009 Nov; 23(11):963-72. PubMed ID: 19786416
[TBL] [Abstract][Full Text] [Related]
18. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
19. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
